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Introduction
Sepsis is the major cause of death in most intensive care units 
in the United States with approximately a quarter of a million 
deaths annually. Although new treatment algorithms focusing on 
rapid administration of broad spectrum antibiotics and aggres-
sive restoration of tissue oxygen delivery have led to decreases 
in mortality, the death rate is still 30%.1,2 Microbial virulence 
factors, the extent of bacterial tissue invasion, and patient 
co-morbidities interact to drive the host response that includes a 
wide array of manifestations including septic shock, adult respi-
ratory distress syndrome (ARDS), multiple organ dysfunction 
syndrome (MODS), and systemic inflammatory response syn-
drome (SIRS).3,4 The heterogeneity of the disease encompasses a 
diverse interplay between immunological stimulation, systemic 
inflammation, and coagulopathy which vary in degree from 
patient to patient.5 This heterogeneity in patient response to sep-
sis is in part responsible for the over 30 failed clinical drug trials; 
beyond supportive care, there is presently no specific Food and 
Drug Administration-approved drug for the treatment of sepsis 
in humans.6 In this review we will focus on (1) the role of the 
adaptive immune system and detail its contribution to the host 
response in sepsis and (2) outline novel potential targets for indi-
vidualized immune therapy in these patients.
Pro-Inflammatory Response: Cytokine Storm
Septic patients frequently present with fever, shock, and respi-
ratory failure due to an uncontrolled pro-inflammatory response 
that has been termed SIRS.7 This initial immune recognition 
response is mediated by pathogen-associated molecular patterns 
(PAMPs) and danger-associated molecular patterns (DAMPs) 
originating from bacterial or fungal organisms and the host 
upon injury, respectively, that bind pattern recognition receptors 
expressed on innate immune cells.3,4,8 The activation of pattern 
recognition receptors results in the production of numerous pro-
inflammatory molecules including TNF-α, IL-1β, IL-2, IL-6, 
IL-8, and IFN-γ and anti-inflammatory cytokines that induce 
a panoply of cellular responses and counter-responses. These 
responses include but are not limited to enhanced phagocytic 
activity, vascular endothelial injury with capillary leak, synthesis 
of acute phase proteins by the liver, chemotaxis of leukocytes to 
sites of infection/inflammation, and activation of the coagula-
tion system.3,4,8,9
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Sepsis remains the leading cause of death in most intensive 
care units. Advances in understanding the immune response 
to sepsis provide the opportunity to develop more effective 
therapies. The immune response in sepsis can be characterized 
by a cytokine-mediated hyper-inflammatory phase, which 
most patients survive, and a subsequent immune-suppressive 
phase. Patients fail to eradicate invading pathogens and are 
susceptible to opportunistic organisms in the hypo-inflam-
matory phase. Many mechanisms are responsible for sepsis-
induced immuno-suppression, including apoptotic depletion 
of immune cells, increased T regulatory and myeloid-derived 
suppressor cells, and cellular exhaustion. Currently in clinical 
trial for sepsis are granulocyte macrophage colony stimulat-
ing factor and interferon gamma, immune-therapeutic agents 
that boost patient immunity. immuno-adjuvants with promise 
in clinically relevant animal models of sepsis include anti-pro-
grammed cell death-1 and interleukin-7. The future of immune 
therapy in sepsis will necessitate identification of the immuno-
logic phase using clinical and laboratory parameters as well as 
biomarkers of innate and adaptive immunity.
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The coagulation system is closely linked to inflammation 
predominately through the innate immune response. In sepsis, 
inflammation is accompanied by coagulation activation, throm-
bin generation, and disseminated intravascular coagulation 
(DIC).10 The primary coagulation pathway activated in sepsis is 
the tissue factor pathway which results in upregulation on mono-
cyte/macrophage membranes and damage to the endothelium.10 
The intrinsic or contact factor pathway amplifies clotting in an 
autoactivation manner leading to widespread vasodilation and 
generation of bradykinin.10 Ultimately, the rapid consumption 
of coagulation factors leads to diffuse hemorrhaging in sepsis.10 
Protease-activated receptors on activated endothelial cells, neu-
trophils, and monocytes bind to thrombin, factor Xa, and tissue 
factor:VIIa which increases the synthesis of pro-inflammatory 
mediators IL-6, IL-8, and adhesion molecules.10 This adhesion 
molecule expression on the vasculature recruits activated leu-
kocytes, in particular activated neutrophils which produce lytic 
enzymes, reactive oxygen species, and nitrogen intermediates 
that contribute to microcirculatory and organ failure.10
Initially the pro-inflammatory response was believed to be 
the major cause of mortality in sepsis and was heavily targeted 
for therapeutic intervention.11 Clinical trials included, for 
example, TNF and IL-1β antagonists, toll-like receptor (TLR) 
blockers, platelet activating factor inhibitors (Xigris12-14), anti-
coagulants, endotoxin antagonists, hemofiltration to remove 
soluble endotoxin and cytokines, and blocking super-antigens 
which ultimately showed no benefit or, in some cases, worsened 
outcome.11,15-17
Hypo-Inflammatory Response: Immuno-Paralysis
As patients survived the initial hyper-inflammatory, cyto-
kine storm phase of sepsis, it became apparent that many sep-
tic patients developed a delayed and potentially prolonged 
counter-regulatory, anti-inflammatory state. This was initially 
referred to as a compensatory anti-inflammatory response syn-
drome (CARS).18-21 After considerable debate, a consensus 
developed that, sepsis can evolve into two phases: the first being 
hyper-inflammation (cytokine storm) and the second being 
hypo-inflammation (immune-paralysis)15,22 (Fig. 1). Although 
inflammation in sepsis is presented as a biphasic view in this 
review, genome-wide transcription profiling in human sepsis has 
indicated that mechanisms of pro- as well as anti-inflammatory 
mechanisms occur during variable times over the course of sep-
sis.23,24 However for the purpose of this review, the biphasic model 
explains the net effect on the inflammatory response, includ-
ing both innate and adaptive immune function, where patients 
may cycle through each phase multiple times over the course of 
sepsis.15 This biphasic view maybe a simplistic explanation of 
a complex disease, yet provides a rational explanation for how 
the function of the immune system becomes altered during the 
course of sepsis. The intensity of the initial hyper-inflammatory 
phase varies depending upon a multitude of factors including the 
patient’s underlying physical state and co-morbidities, pathogen 
virulence factors, pathogen load, and genetic factors. Following 
this, perhaps in an effort to dampen systemic inflammation, sub-
sequent immunosuppression may develop. As with the uncon-
trolled initial inflammation, this may overshoot and result in 
immune dysfunction that leads to increased host susceptibility 
to secondary bacterial infections (ventilator-associated pneumo-
nia [VAP]),25 infections with typically avirulent or opportunistic 
organisms,26,27 reactivation of latent herpes viruses (cytomegalo-
virus [CMV]),28-30 increased risk of MODS,31 and loss of delayed 
type hypersensitivity response to common recall antigens.32 
Research by many groups has shown that hypo-inflammation 
is due to a variety of immune defects including a dysfunctional 
adaptive immune response.15,33-40
The adaptive immune system consists of specialized cells 
that are antigen specific and critical for generating memory and 
recall responses to antigens. Antigen-specific T cells are neces-
sary for driving specific responses against intracellular (T-helper 
1 [Th1]) or extracellular pathogens (T-helper 2 [Th2]) by cell-
to-cell contact mechanisms or through soluble mediators (cyto-
kines). CD4 T cells are typically classified as helper T cells 
and control cells of the adaptive system. CD8 T cells are clas-
sified as cytotoxic (CTL) and kill targeted cells such as virally 
infected or tumor cells. Antibody production, termed humoral 
Figure  1. immune response in sepsis. The immune response in sepsis 
is determined by many factors including co-morbidities (i.e., diabetes, 
heart disease, malignancy) as well as the pathogen virulence and size 
of the microbial inoculums. Although both pro- and anti-inflammatory 
processes are activated simultaneously during the onset of sepsis, dur-
ing the first few days, a hyper-inflammatory response often dominates 
the clinical picture. The hyper-inflammatory phase has been termed a 
“cytokine storm” that is indicated by increased levels of TNF-α, iL-1β, 
and iL-6. A robust depletion of both innate and adaptive immune cells 
through apoptosis occurs to dampen the response. (A) At this stage, 
patients may undergo a controlled anti-inflammatory response enabling 
them to return to immune homeostasis. Alternatively, patients may 
undergo an uncontrolled anti-inflammatory response and enter a hypo-
inflammatory phase yet survive (B) or succumb. Protracted time spent in 
this hypo-inflammatory phase may lead to cellular exhaustion; a cellular 
phenotype indicated by impaired function as well as increased PD-1 and 
decreased iL-7R expression on T lymphocytes. in this phase, patients fail 
to mount proper immune responses leading to viral re-activation and 
secondary infections, frequently caused by avirulent and opportunistic 
organisms and of ventilator-associated pneumonia.
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immunity, by B cells requires T-cell help. Antigen-specific anti-
body can neutralize toxins, fix complement, and coat the surface 
for phagocytic uptake of pathogens by monocytes/macrophages. 
Antigen-presenting cells, including monocyte/macrophages and 
dendritic cells, sample the environment and present antigens to 
T cells for initiation of immune responses or induction of tol-
erance of the adaptive immune response. The effects of sepsis 
on the adaptive immune response and the potential therapeutic 
advantage of targeting these components during the pathogenesis 
of sepsis will be the focus of the following sections.
Adaptive Immunity: Apoptosis 
of Immune Effector Cells
Programmed cell death, also called apoptosis, is one way in 
which the immune system maintains homeostasis by eliminat-
ing activated cells. Central to apoptosis are caspases which are 
cysteine proteases that degrade cellular proteins and NFκB, a 
transcription factor which will activate transcription of both pro-
apoptotic and pro-survival genes. While the hyper-inflammatory 
response of sepsis requires NFκB for production of pro-inflam-
matory cytokines and IL-1β activation by caspase cleavage, both 
NFκB and caspases concurrently induce apoptosis of adaptive 
immune cells.8,41,42 Consistent with this, a concurrent apoptotic 
response has been shown to be present in sepsis in association 
with the pro-inflammatory response. Our group has shown both 
in mouse models of sepsis43,44 as well as most recently in patients 
with severe sepsis that there is a profound depletion of T, B, and 
dendritic cells.45-48 Within the first 24 h of sepsis diagnosis in 
humans, marked lymphopenia occurs which is due to recruit-
ment of lymphocytes from the circulation to sites of inflam-
mation/infection and to apoptotic depletion of CD4 and CD8 
T cells in the blood.45 Postmortem analysis of spleens and lymph 
nodes from individuals who succumbed to sepsis confirmed the 
highly significant loss of CD4 and CD8 T cells.46 Memory CD8 
T cells are highly susceptible to apoptosis in systemic inflamma-
tory states such as septic shock and are depleted in sepsis.49 These 
results indicate that depletion of adaptive immune cells is a major 
pathologic component of sepsis with potential debilitating effects 
on host immunity.
Although the depletion of adaptive immune cells is recog-
nized as an important part of the pathology of sepsis, the mech-
anisms responsible for this are not totally understood.50,51 In 
general apoptosis is divided into two mechanistic pathways, i.e., 
an extrinsic pathway that conveys a signal through a death recep-
tor such as the tumor-necrosis family of receptors (i.e., CD95/
CD95L, TNF/TNFR) or an intrinsic pathway that disrupts 
mitochondrial integrity resulting in release of cytochrome C.52,53 
The activation of caspase 8, through death domains, and/or the 
activation of caspase 9, by the release of cytochrome C, results 
in the cleavage and activation of caspase 3 an effector caspase 
that induces extensive substrate cleavage of many critical proteins 
ultimately leading to cell death.52,53 These pathways of apoptosis 
have multiple points of crosstalk.54 Bid, a member of the Bcl-2 
family of proteins, is cleaved by activated caspase-8, an effector 
of the extrinsic pathway, to form truncated Bid.54 This truncated 
Bid translocates to the mitochondrion where it binds Bax/Bak, 
members of the Bcl-2 family associated with the intrinsic path-
way, to further induce apoptosis.54 Heat-shock proteins can either 
be constitutively expressed or rapidly induced in response to 
stress, like inflammation, yet modulate both the mitorchondrial 
and receptor mediated apoptotic pathways.54 Adaptor molecules 
like receptor interacting protein (RIP) or members of the TNF 
receptor-associated factor family (TRAF) activate transcrip-
tion factor families associated with both survival and apoptosis 
including NFκB and mitogen-activated protein kinase (MAPK) 
pathways.54 To add to this complexity, a wide range of protein 
modifications and interactions form diverse yet interconnected 
signaling cascades that regulate signaling pathways such as PI3K-
Akt/PKB, Ras-Raf-Mek-Erk MAPK, NFκB, and protein kinase 
C that are pro-survival while JNK/p38 stress MAPK or ROS/
ceramide-mediate signaling which are pro-apoptotic.54
As noted earlier, CD4 and CD8 T cells are highly susceptible 
to sepsis-induced apoptosis. To test the premise that soluble fac-
tors induce lymphocyte apoptosis in sepsis, serum from patients 
with SIRS was added to cultures of lymphocytes from healthy 
volunteers. Apoptosis of CD4 T cells was observed when plasma 
from SIRS patients was added but apoptosis was not present 
when serum from healthy donors was used.55 Although this sol-
uble factor has yet to be identified, it is likely that a multitude of 
soluble factors are involved in modulating lymphocyte apoptosis. 
Some gram-positive bacteria have a unique property, an exotoxin 
termed a superantigen that activates CD4 T cells through a tet-
rad signaling complex consisting of a correctly folded superan-
tigen, the CD28 dimer interface, Vβ loop of the TCR, and a 
binding site outside the epitope presenting groove on MHC class 
II molecules.56 This interaction occurs independent of MHC-
Class II molecules and results in rapid activation, secretion of 
pro-inflammatory cytokines and ultimately cell death.8 In poly-
microbial sepsis the activation of the peroxisome proliferator acti-
vated receptor (PPARγ) leads to decreased IL-2 gene expression, a 
T-cell survival factor that induces expression of the potently anti-
apoptotic protein Bcl-2.57 The massive release of TNF-α early in 
sepsis results in activation of additional pro-inflammatory cyto-
kines and chemokines which act in conjunction with TNF-α to 
induce T-cell apoptosis.58 In mouse models of sepsis, the comple-
ment factor C5a binds to the receptor C5aR on thymocytes and 
induces apoptosis.59 Therefore, in sepsis a diversity of soluble fac-
tors are present that potentially regulate apoptosis and add to the 
heterogeneity of sepsis pathology.
Lymphocyte fate is determined by the balance of pro- vs anti-
apoptotic mechanisms. In our postmortem study of sepsis, we 
documented decreased expression of CD28 on T lymphocytes 
on septic patients when compared with control patients.46 The 
co-stimulatory molecule CD28, when engaged by B7 molecules 
on antigen presenting cells, is an essential requirement for IL-2 
production and Bcl-X
L
 expression, both pro-survival factors of 
T cells.60 Antigen-presenting cells, including dendritic cells and 
monocytes/marcrophages, isolated from either the spleen or the 
lung of septic patients also had decreased expression of B7 mole-
cules (B7-1/CD80 and B7-2/CD86) potentially limiting the abil-
ity of T cells to receive co-stimulation.46 Without the necessary 
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co-stimulation through CD28/B7 when the T-cell receptor 
engages antigen, T cells will undergo a process termed death by 
neglect or become functionally unresponsive (anergic).
Our recent studies have also indicated that T cells upregu-
late surface receptors that inhibit T-cell functions. We iden-
tified increased expression of programmed death receptor-1 
(PD-1), CTLA-4, and B and T lymphocyte attenuator (BTLA) 
on T cells when isolated from postmortem spleen and lung as 
well as from blood 7 days after initial diagnosis with sepsis.45,46 
Furthermore, we detected increased expression of the ligands for 
PD-1, programmed death ligand-1 and -2 (PD-L1 and PD-L2), 
on antigen-presenting cells isolated from the blood after 7 days 
of initial septic diagnosis and from lymphocytes isolated from 
post-mortem spleen and lung.45,46 The expression of PD-L and 
herpesvirus entry mediator (HVEM), the ligand for BTLA, was 
observed on the epithelium and on macrophages of the lung in 
septic patients.45,46 The expression of PD-L on antigen presenting 
cells and endothelial cells has been associated with the induc-
tion of tolerance,61,62 providing a mechanism where the tissue 
regulates lymphocyte homeostasis. The engagement of PD-1, 
CTLA-4, or BTLA, all members of the CD28-superfamily of 
receptors, results in T-cell apoptosis or cellular unresponsiveness 
that aid in returning the host to immune homeostasis.63 PD-L 
and CTLA-4 as well as TNFR ligand family members such as 
Fas-Ligand (CD95L) are expressed on a specialized type of CD4 
T cell that expresses the transcription factor FoxP3 and high sur-
face levels of CD25 (IL-2Rα) termed regulatory T cells (Tregs).64 
Regulatory T cells are capable of suppressing T-cell proliferation, 
cytokine secretion and induce T-cell apoptosis.65 These cells are 
increased in percentage in septic patients due to their resistance 
to apoptosis and a decrease in CD4+CD25− T cells35,36,45,66,67 pro-
vides yet another potential mechanism of immune dysfunction. 
The expression of these inhibitory receptors/ligands on T cells, 
antigen presenting cells and tissue presents an environment that 
is conducive to T-cell depletion and unresponsiveness in septic 
patients.
Adaptive Immunity: Cellular Hypo-Responsiveness
The anti-inflammatory cytokine IL-10 has been detected in 
serum of septic patients very early during their illness.68 A high 
ratio of IL-10 to TNF-α in septic patients correlated with mor-
tality in patients with community acquired infection.68,69 The 
anti-inflammatory cytokine IL-10 is produced by Tregs and Th2 
type cells and suppresses the Th1 (CD8 T cell) response further 
potentiating an anti-inflammatory environment.70,71 This sup-
pressive environment results in a marked decrease in stimulated 
monocyte production of pro-inflammatory cytokines TNF-α, 
IL-1β, and IL-6 (typically less than 10–20% that of healthy 
controls).72-76 This compensatory anti-inflammatory response 
syndrome, or immune-paralysis as it was originally referred to, 
is mediated by a predominance of a Th2 response, increased 
Tregs, apoptosis of lymphocytes and decreased MHC class II 
(HLA-DR) molecules on monocytes/macrophages.10,18 Our 
group reported that immune effector cells isolated from postmor-
tem spleens with patients dying of sepsis and peripheral blood 
mononuclear cells isolated from blood of septic individuals 7 days 
after onset of sepsis have impaired secretion of both pro- and 
anti-inflammatory cytokines (TNF-α, IFN-γ, IL-6, IL-10).45,46 
Furthermore, this cytokine secretion defect in septic patients was 
present after stimulation with lipopolysaccharide (a monocyte/
macrophage activator) and after stimulation with anti-CD3/anti-
CD28 (a T-cell activator) indicating that both the innate and 
adaptive immune systems are suppressed.45,46
Adaptive Immunity: Cellular Exhaustion
Both the postmortem and prospective blood study, previously 
discussed, demonstrated that T lymphocytes from septic patients 
expressed inhibitory receptors and that these T cells were unable 
to produce cytokines after ex vivo stimulation.45,46,77 In the post-
mortem study, T cells isolated from the spleen had increased 
expression of CD69, PD-1, and CD25 and decreased expression 
of the IL-7 receptor (IL-7R, CD127) and CD28 when compared 
with age-matched controls.46 T cells isolated from the lung had 
increased expression of PD-1 and BTLA indicating a degree of 
tissue specificity in sepsis.46 Furthermore, increased expression of 
inhibitory receptors, PD-1, BTLA, CTLA-4, T cell membrane 
protein-3 (TIM-3), lymphocyte-activation gene-3 (LAG-3), and 
decreased expression of the IL-7R on T cells isolated from the 
blood of septic patients occurs over the course of sepsis.45 This 
expression of inhibitory receptors and decreased cytokine secre-
tion resemble a recently described phenotype observed in chronic 
viral infections like HIV and hepatitis C that is termed cellular 
exhaustion.
T-cell exhaustion is a step-wise progressive loss of T-cell func-
tions in the presence of high antigen load that can result in T-cell 
deletion.78 Originally described in the lymphocytic choriomen-
ingitis virus (LCMV) mouse model, T-cell exhaustion has also 
been documented in HIV, hepatitis C, hepatitis B, polyoma 
virus, adenovirus, Friend leukemia virus, and in malignancies.78 
Exhausted T cells have high expression of CD69, CD43 (1B11), 
PD-1, TIM-3, and LAG-3, low expression levels of CD62L and 
CD127 (IL-7R), increased expression of the transcription fac-
tor BLIMP-1 (CD8 T cells) and decreased secretion of TNF-
α, IL-2, IFN-γ, and Granzyme B.78 The engagement of PD-1 
by its ligands on exhausted T cells results in IL-10 production, 
functional unresponsiveness and/or apoptosis.78 In sepsis, there 
is high antigen load due to chronic infection, T cells acquire 
expression of inhibitory receptors over time, as well as the expres-
sion of inhibitory ligands on antigen presenting cells and in a 
tissue-specific manner, provide a unique environment for T-cell 
exhaustion as an additional mechanism of immune suppres-
sion in sepsis.45,46 In support of this concept of sepsis-induced 
T-cell exhaustion, tissue expression of PD-L and HVEM the 
ligands for PD-1 and BTLA on T cells was present in the lungs 
of septic individuals but not in lungs of transplant recipients or 
age-matched non-septic control patients.46 These findings are 
particularly relevant given the high incidence of ventilator asso-
ciated pneumonia which is the most common nosocomial infec-
tion in the intensive-care unit.79-81 The increased susceptibility 
of the lung to secondary infection in septic patients may be due 
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in part to expression of inhibitory ligands on lung parenchyma 
resulting in local T-cell exhaustion.
Immuno-Therapy: Targeting the 
Adaptive Immune System
Despite active research in understanding human sepsis, the 
number of registered human clinical trials is disappointing, 
with most observational in nature and few being interventional 
(Table 1). Many septic patients have a relatively short-lived 
hyper-inflammatory phase; therefore, the success of drugs target-
ing inflammation has only a narrow time frame to be effective. 
The keys to drugs targeting this hyper-inflammation are: drugs 
should be short lived, applied early and used only in patients 
with elevated levels of pro-inflammatory cytokines (i.e., TNF-
α, IL-1β, or IL-6).3,4 Phase I–III clinical trials using drugs to 
reduce this pro-inflammatory cascade have had disappointing 
results in 28-day mortality rates in septic patients when com-
pared with placebo-treated controls.14,17,82-90 Most septic patients 
residing in ICUs have survived the hyper-inflammatory stage 
of the disease yet have prolonged periods of hospitalization and 
recovery with the potential to become immune compromised 
and develop nosocomial infections and/or multiorgan dysfunc-
tion.34,91,92 Therefore, one of the keys to decreasing mortality 
in sepsis may be the development of therapies to augment host 
immune responses. Collectively, results of studies designed to 
block this hyper-inflammatory phase suggest partial benefit in 
early onset sepsis in highly-defined populations of septic patients 
yet are potentially detrimental to septic patients who have pro-
gressed into immune-paralysis.15,33
Even before the molecular pathophysiology of sepsis was 
thoroughly understood, investigators attempted to stimulate the 
innate and adaptive immune systems with IFN-γ, granulocyte 
macrophage colony stimulating factor (GM-CSF) or granulocyte 
colony stimulating factor G-CSF. In an attempt to reverse mono-
cyte/macrophage dysfunction and increase IL-17, a cytokine nec-
essary for the recruitment of neutrophils to the infected site, septic 
patients were treated with IFN-γ.93 Treatment with GM-CSF was 
also predicted to reverse the dysfunction of dendritic cells and 
macrophages/monocytes.94 G-CSF was utilized to increase num-
bers of polymorphonuclear leukocytes, in an effort to enhance 
pathogen clearance. Although a recent meta-analysis performed 
on GM-CSF and G-CSF studies conducted from 1998 to 2011 
failed to show survival benefit,95 some studies did show limited 
efficacy on research endpoints.96-105 In summary, GM-CSF or 
G-CSF treatment increased neutrophil phagocytosis, resolved 
infections earlier, decreased secretion of toxic metabolites, 
increased expression of CD11b and HLA-DR on neutrophils/
monocytes, and reversed immune-paralysis in selected septic 
patients.3,4 Two recent small phase 2 trials of GM-CSF that have 
targeted its use to septic patients with low monocyte HLA-DR 
expression have shown benefit. Mechanically-ventilated patients 
with sepsis that received GM-CSF had improved health evalu-
ation scores, shortened time of mechanical ventilation, and an 
Table 1. immune enhancing therapy: clinical trials in sepsis
Agent Study Outcomes References
G-CSF
RCT in patients with pneumonia and severe 
sepsis
increased wBC counts
No reduction in mortality
well tolerated
Root et al.103
G-CSF RCT in patients with multilobar pneumonia
increased wBC counts




RCT in patients with sepsis or septic shock and 
sepsis induced immunesuppression
increased HLA-DR expression





effects of immunostimulation with GM-CSF or 
iFN-γ on immunoparalysis following human 
endotoxemia






riFN-γ RCT in trauma patients
increased HLA-DR expression
Decreased severe infections (trend)
Polk et al.106
riFN-γ RCT in patients with burns No improved patient outcomes wasserman et al.107
riFN-γ RCT in trauma patients Reduced infection related deaths Dries et al.108
riFN-γ (ongoing)
effects of interferon-gamma on sepsis-induced 
immunoparalysis
Cytokine secretion by lymphocytes
HLA-DR and receptor expression (PD-1)
Lymphocyte gene expression
Reversibility of monocyte dysfunction
Patient outcomes
NCT01649921
Thus far, the focus of enhancing immune function in sepsis has been limited to trials for GM-CSF or G-CSF, a stimulator of the innate immune system, and 
iFN-γ, a stimulator of the adaptive immune system. Abbreviations: RCT, randomized controlled trial; GM-CSF, granulocyte-macrophage colony-stimulat-
ing factor; G-CSF, granulocyte colony-stimulating factor; riFN-γ, recombinant interferon gamma; PD-1, programmed death receptor-1; wBC, white blood 
cell count; NCT, ClinicalTrials.gov identifier.
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accompanied increased HLA-DR expression and in secretion 
of pro-inflammatory cytokines (IL-6 and TNF-α) ex vivo as 
compared with controls.105 At least 2 clinical trials of GM-CSF 
are currently enrolling patients in sepsis (NCT01374711 and 
NCT01653665, Table 2), so it will be highly interesting to 
observe these results when they become available.
Thus far, the only attempt to modulate the adaptive immune 
response in a sepsis clinical trial was the administration of IFN-γ 
(Table 2). Treatment with IFN-γ in critical illness has yielded 
conflicting results. In two multi-center trials with patients of 
trauma and burns, treatment with IFN-γ had no effect when 
compared with placebo.106,107 However, in an additional trial in 
burn patients, IFN-γ treatment reduced infection-related deaths 
when compared with placebo.108 Interestingly, when IFN-γ was 
co-administered with GM-CSF to those septic patients whose 
mononcytes had decreased HLA-DR expression of less than 35% 
of normal, therapy raised HLA-DR co-expression up to ~50% 
and restored TNF-α secretion from ex vivo stimulated periph-
eral blood mononuclear cells.109 These results further confirm 
the importance of knowing the relative pro- and anti-inflamma-
tory balance of the septic patients before administering immune 
therapies in sepsis. In our prospective study of septic patients, 
IFN-γ was determined to be the cytokine that was significantly 
decreased at the earliest time point following sepsis onset.45 
Furthermore, peripheral blood mononuclear cells isolated from 
septic individuals that were rested overnight in fresh media 
Table 2. Clinical trials for the immune system in sepsis
Identifier Title Study type Sponsor
NCT01600989
Mitochondrial Function of immune Cells in Sepsis (MitoSepsis) 
(2012)
Observational University Hospital inselspital
NCT01530932
immune Activation, Hypoxia and vasoreaction in Sepsis of 
Pulmonary vs. Abdominal Origin (2011)
Observational University Hospital Mannheim
NCT00187824
Regulation of endocrine, Metabolic, immune and Bioenergetic 
Responses in Sepsis (2005)
Observational University College London Hospital
NCT01410526
Assessment of Peritoneal immune Response in Patients with 
Severe intra-abdominal Sepsis Managed with Laparostomy 
and vacuum Assisted Closure (vAC) (2011)
Observational Aristotle University of Thessaloniki
NCT01472952
System-level Monitoring of immune Activation Concerning 
Susceptibility to Sepsis in Trauma Patients (2011)
Observational University Hospital Mannheim
NCT01155674 innate immune Functions of immature Neutrophils (2010) Observational University Hospital Geneva
NCT01766414
in vivo effects of C1-esteraase inhibitor on the innate immune 
Response During Human endotoxemia – veCTOR ii (2013)
interventional Radboud University
NCT01649921
The effects of interferon-gamma on Sepsis-induced 
immunoparalysis (2012)
interventional Radboud University
NCT00294697 Genetic variation and immune Response After injury (2006) Observational
National institute of General Medical 
Sciences
NCT00638521 immune-cell Membrane Trafficking (2008) Observational University of washington
NCT01099813
Sepsis Pathophysiological and Organisational Timing 
(SPOT[Light]) (2010)
Observational
intensive Care National Audit and 
Research Centre
NCT01756755
endotoxin Adsorber Hemoperfusion and Microcirculation 
(2012)
interventional National Taiwan University Hospital
NCT01275976
effect of C1-esterase inhibitor on Systemic inflammation in 
Trauma Patients with a Femur Fracture (CAeSAR) (2011)
interventional UMC Utrecht
NCT01005589
CD64 Meaurement in Neonatal infection and Necrotising 
enterocolitis (2009)
Observational
Newcastle-upon-Tyne Hospitals NHS 
Trust
NCT00527384 Biomarker Analysis of Stress (2007) Observational
National institute of environmental 
Health Sciences
NCT01397058
Reactivation of CMv infection in immunocompetent Patients 
Under Severe Stress (ReCYSTReSS) (2011)
Observational University of Athens
NCT01374711
effects of immunostimulation with GM-CSF or iFN-γ on 
immunoparalysis Following Human endotoxemia (2011)
interventional Radboud University
NCT01653665
Does GM-CSF Restore Neutrophil Phagocytosis in Critical 
illness? (2012)
interventional
Newcastle-upon-Tyne Hospitals NHS 
Trust
A search on ClinicalTrials.gov was performed using the search terms “Sepsis and immune” (48 studies) or “Sepsis and Biomarkers” (74 studies) filtered by 
“open studies”. This represents a list of the current open and enrolling clinical trials for sepsis in regards to the immune system. interestingly, most clinical 
trials in sepsis have been initiated within the past 10 years as indicated by the start date of the clinical trial in parenthesis following the trial title.
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recovered their ability to secrete IFN-γ in response to ex vivo 
stimulation.45 These data suggest depressed secretion of IFN-γ is 
an early indicator of hypo-inflammation and may be a reversible 
defect in lymphocytes; therefore, pathways that augment IFN-γ 
may be good potential therapeutic targets. Currently Radboud 
University in the Netherlands is conducting an IFN-γ trial in 
sepsis to study the effects on “sepsis-induced immunoparalysis”, 
which will be completed in December 2013 (ClinicalTrials.gov; 
NCT01649921).
In addition to GM-CSF, G-CSF, and IFN-γ, other novel 
immune-adjuvant therapies may be effective in augmenting the 
adaptive immune system and restoring immunity. The profound 
apoptosis-induced depletion of lymphocytes in sepsis is one such 
attractive therapeutic target. The pro-survival cytokines IL-7 
and IL-15 have had promising results in sepsis models in pre-
venting lymphocyte apoptosis and restoring adaptive immunity. 
In a mouse model of sepsis, IL-15 treatment increased lympho-
cyte survival, decreased apoptosis of natural killer cells, dendritic 
cells, and T cells, and increased IFN-γ secretion.110 The adminis-
tration of IL-15 may have additional benefits of increasing natu-
ral killer and dendritic cell survival111,112 whereas IL-7 is thought 
to be a more T cell targeted cytokine.113
Currently, the most promising cytokine in restoring T-cell 
function in a variety of disease states is IL-7. IL-7 is a plu-
ripotent cytokine of the immune system that affects both T 
and B cells and induces proliferation of naïve and memory T 
cells.113,114 Administration of IL-7 by investigators at the National 
Cancer Institute to cancer patients led to a doubling of CD4 
and CD8 T cells, did not expand regulatory T cells, and led to 
a corresponding increase in spleen and lymphnodes by roughly 
50%.115-117 Recombinant IL-7 was also effective in inducing a 
doubling of circulatory CD4 and CD8 T cells in patients with 
lymphopenia due to HIV.118 Several groups including ours have 
shown that IL-7 treatment of mouse models of sepsis results in 
increased lymphocyte numbers, restored delayed type hypersen-
sitivity responses, decreased lymphocyte apoptosis, reversed the 
impaired IFN-γ secretion of lymphocytes and improved sur-
vival.93,119,120 Furthermore, work by Venet et al. showed that IL-7 
treatment of isolated lymphocytes from septic patients restored 
T-cell proliferation, IFN-γ secretion, STAT5 phosphorylation 
(an important downstream signaling molecule of the IL-7R), and 
Bcl-2 expression close to that of healthy controls.121 Treatment of 
HIV and cancer patients with hIL-7 has indicated IL-7 is well 
tolerated with less side effects then IL-2, another pro-survival 
cytokine for T cells, and has diverse effects including: increases 
in T-cell survival, restores function in exhausted T cells a pheno-
type identified in sepsis,77 increases expression of adhesion mol-
ecules and therefore trafficking to sites of infection, and increases 
T cell receptor diversity thereby increasing pathogen recogni-
tion.118,122-124 Due to the diverse effects of IL-7 on the adaptive 
immune system and its good safety clinical profile, IL-7 has been 
consistently ranked as one of the top therapeutic molecules by 
the NCI.125 Therefore, we believe clinical trials of IL-7 in sepsis 
should be initiated.
Common to most septic patients is increased expression of 
PD-1 on T cells over the progression from hyper-inflammation 
to hypo-inflammation. As noted earlier, signaling through 
PD-1 inhibits T-cell proliferation, induces IL-10 secretion, 
induces apoptosis and anergy, and inhibits cytotoxicity of CD8 
T cells.126,127 Four independent groups have shown that disrup-
tion of the PD-1/PD-L axis either by genetic deletion or by 
pharmacologic manipulation improved survival in bacterial and 
fungal murine sepsis.128-131 In both our prospective and post-
mortem studies of septic patients, PD-1 expression was increased 
on CD4 and CD8 T cells while PD-L expression was increased 
on antigen presenting cells as well as on the tissue of the spleen 
and lung45,46 indicating this PD-1/PD-L axis is present and may 
be dysregulated in human sepsis. Furthermore, PD-1 overexpres-
sion on T cells from septic patients correlated with decreased 
T-cell proliferation, increased secondary infections and mortal-
ity.132 In oncology, anti-PD-1 and anti-PD-L antibody therapy 
has been used successfully to treat various tumors in 20–25% of 
treated patients.133,134 These data indicate that blocking the PD-1/
PD-L axis is a promising target for restoring immune function in 
human sepsis.
As T-cell exhaustion is defined by the expression of multiple 
inhibitory receptors, not just PD-1 expression, the development 
of blocking antibodies to these additional receptors may also be 
promising in sepsis.77 For example the BTLA/HVEM axis also 
a negative regulator of T-cell responses135,136 is also present in 
human sepsis. Interestingly, T cells express BTLA while tissue 
of the lung, a common site of secondary nosocomial infections 
including ventilator-associated pneumonia, expresses HVEM.45,46 
BTLA deficient mice have increased survival in a mouse model 
of sepsis,137 providing another immunologic target for ventilator 
associated pneumonia and sepsis. Additional receptors associated 
with T-cell exhaustion such as TIM-3, LAG-3, and CTLA-4 
may also provide therapeutic targets in restoring T-cell functions. 
Cellular exhaustion is a characteristic not only of chronic viral 
infections but of cancer biology due to the presence of high anti-
gen load.138 In mouse models of tumor formation, anti-TIM-3 
therapy reduced tumor burden and increased IFN-γ secretion 
and cytotoxic ability of tumor-specific CD8 T cells.139,140 In 
addition to TIM-3, LAG-3 therapy has shown promising results 
in treating human cancers by restoring anti-tumor responses 
of T cells.141 With our rapidly expanding knowledge of T-cell 
exhaustion and the role of these inhibitory receptors in lympho-
cyte function, the potential for biologics that modulate the adap-
tive immune system and restore lymphocyte function in sepsis 
offers great promise (Fig. 2).
In the not too distant future, one can imagine a way to geneti-
cally manipulate T cells for the treatment of sepsis. Genetically 
modified T cells are currently in trial for the treatment of her-
pes viral infections in transplant patients (ClinicalTrials.gov; 
NCT01646645 and NCT01535885). These T cells have been 
manipulated to be specific against viral specific antigens.142 In 
sepsis, a modified T cell resistant to apoptosis and polyclonal 
for a variety of pathogens, including bacterial, fungal and viral, 
could be transfused during immune dysfunction to restore 
patient immunity. Preliminary evidence in mouse models of sep-
sis using genetically modified T cells that overexpress Bcl-2143-145 
or Akt146 have resulted in increased T cell and mouse survival. 
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Modified T cells incorporating a suicide gene would enable only 
the modified T cells to be destroyed once the infection is cleared 
leaving the patient’s own immune system intact.147,148 This would 
eliminate a potential concern of autoimmunity from long-term 
antibody therapy.
Final Thoughts: Immune-Enhancing Therapy
Many trials using immune-modulatory agents have yielded 
discouraging results in human clinical trials for sepsis.3,4 One 
reason for this failure is that animal studies may not always cor-
relate with the human condition. As the majority of sepsis mod-
els use genetically similar young mice, confounding problems 
that are often present in clinical sepsis like age, genetic diversity, 
underlying co-morbidities, various sites of infections, suscepti-
bility to virulence factors, and management protocols including 
nutrition and antibiotic usage are not accounted for.3,4,149,150 This 
heterogeneity of human sepsis is in part what makes performing 
clinical trials and their success very difficult to achieve. Recently, 
genetic profiling of inflammatory diseases in humans and mice 
have indicated that mouse gene transcriptional changes occur-
ring in sepsis do not correlate with the human condition.151 These 
data indicate the need to undertake more human translational 
approaches to better our understanding of the underlying molec-
ular pathophysiology of sepsis (Table 1).
To monitor sepsis in humans, clinical trials are currently 
underway to elucidate biomarkers that can identify patients who 
have increased or decreased inflammation (ClinicalTrials.gov, 
Table 1). Importantly, the kinetics of expression of the targeted 
receptors (i.e., PD-1/PD-L, HVEM/BTLA) as well as patient’s 
immune status needs to be fully understood so that therapy 
can be employed effectively. For example, inhibition of IL-10 
in patients with increased inflammation dramatically increased 
pro-inflammatory cytokines with detrimental effects.152 Clinical 
trials that monitored HLA-DR expression as an indicator of 
immune function had moderate success in improving outcomes 
in sepsis.105,109 Therefore, a combination of flow cytometry for 
lymphocyte expression of surface receptors (i.e., HLA-DR, 
PD-1), functional assays for cytokine secretion (IFN-γ) as 
well as presence or absence of nosocomial infections (ventilator 
Figure 2. Pathways of immune dysfunction and targets for immune enhancing therapy in sepsis. in the initial pro-inflammatory response of sepsis, 
both the adaptive and innate immune systems are rapidly activated. This activation of monocytes, dendritic cells (DC), and macrophages (MAC), as well 
as CD4 helper and CD8 cytotoxic T cells results in the release of pro-inflammatory cytokines (TNF, iL-6, iL-1β) and chemokines. This pro-inflammatory 
response normally results in cellular activation and clearance of the primary pathogen (~~, pathogen). in the instance of a healthy individual, the immune 
system maintains homeostasis by employing counter inflammatory mechanisms such as regulatory T cells (Tregs), apoptosis, production of cytokines, 
expression of inhibitory receptors and myeloid-derived suppressor cells (MDSC) concurrently during inflammation. However, in some septic patients 
these normal homeostatic counter inflammatory mechanisms remain elevated such as expression of inhibitory receptors including: programmed death 
receptor -1 (PD-1), programmed death ligand (PD-L), B and T lymphocyte attenuator (BTLA), and herpesvirus entry mediator (HveM) as well as the 
production of the immune modulating cytokine iL-10. immune dysfunction occurs as activated innate and adaptive immune cells undergo rapid apop-
tosis while in the presence of increased suppressor cell populations like Tregs or MDSC. The primary infection fails to be cleared and may progress into 
immune suppression. Prolonged immune suppression and persistent antigen may result in T-cell exhaustion indicated by a T cell’s increased expression 
of PD-1 and decreased expression of the iL-7R as well as a functional impairment that includes failure to proliferate, secrete cytokines, and kill target 
cells. Potential targets for immune-therapy are indicted in the dotted GReeN line. Potential therapeutic targets include using blocking antibodies such 
as anti-iL-10 to decrease Treg function; anti-PD-1 and anti-PD-L to reverse the induction of T-cell exhaustion; and anti-HveM or anti-BTLA to block tissue 
suppression of immune cells. iL-7 or iL-15 may be effective in blocking apoptosis and reversing cell exhaustion; GM-CSF to stimulate APC function by 
increasing recruitment and HLA-DR expression; and iFN-γ to increase PMN recruitment and function.
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pneumonia, Candida spp.) and reactivation of latent viruses (i.e., 
herpes viruses) may help to guide patient immune-therapy.
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